Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.

Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, Holland EC, Galbán CJ, Ross BD.

PLoS One. 2012;7(4):e35857. doi: 10.1371/journal.pone.0035857. Epub 2012 Apr 20.

2.

Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.

Kim JH, Choi SH, Ryoo I, Yun TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH.

PLoS One. 2014 Nov 24;9(11):e113587. doi: 10.1371/journal.pone.0113587. eCollection 2014.

3.

Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.

Hadjipanayis CG, Fellows-Mayle W, Deluca NA.

Mol Ther. 2008 Nov;16(11):1783-8. doi: 10.1038/mt.2008.185. Epub 2008 Aug 26.

4.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
5.

Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, Jung SC, Lee AL, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH.

Radiology. 2013 Dec;269(3):831-40. doi: 10.1148/radiol.13122024. Epub 2013 Oct 28.

PMID:
23771912
6.

Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.

Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, Faber C, Kopka K, Schäfers M, Jacobs AH.

PLoS One. 2013 Jul 4;8(7):e67911. doi: 10.1371/journal.pone.0067911. Print 2013.

7.

Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.

Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1066-74. doi: 10.1016/j.ijrobp.2010.07.021. Epub 2010 Oct 6.

PMID:
20932651
8.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

9.

Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.

Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM.

Neuro Oncol. 2014 Mar;16(3):414-20. doi: 10.1093/neuonc/not198. Epub 2013 Dec 4.

10.

Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.

Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.

PMID:
22483738
11.

Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.

Saito K, Mukasa A, Narita Y, Tabei Y, Shinoura N, Shibui S, Saito N.

Neurol Med Chir (Tokyo). 2014;54(4):272-9. Epub 2013 Nov 20.

12.

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.

Lemasson B, Wang H, Galbán S, Li Y, Zhu Y, Heist KA, Tsein C, Chenevert TL, Rehemtulla A, Galbán CJ, Holland EC, Ross BD.

Neoplasia. 2016 Feb;18(2):82-9. doi: 10.1016/j.neo.2015.11.014.

13.

Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.

Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9. doi: 10.1016/j.ijrobp.2009.04.026.

14.

Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.

Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD.

J Neurosurg. 2007 Sep;107(3):610-6.

PMID:
17886562
15.

Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.

Sheehan J, Cifarelli CP, Dassoulas K, Olson C, Rainey J, Han S.

J Neurosurg. 2010 Aug;113(2):234-9. doi: 10.3171/2009.11.JNS091314.

PMID:
20001586
16.

The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.

Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW.

J Neurooncol. 2013 Apr;112(2):277-83. doi: 10.1007/s11060-013-1060-3. Epub 2013 Feb 2.

PMID:
23377829
17.

Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.

Gutenberg A, Bock HC, Reifenberger G, Brück W, Giese A.

Acta Neurochir (Wien). 2013 Mar;155(3):429-35. doi: 10.1007/s00701-012-1583-y. Epub 2012 Dec 20.

PMID:
23254891
18.

Radiotherapy with and without temozolomide in elderly patients with glioblastoma.

Niyazi M, Schwarz SB, Suchorska B, Belka C.

Strahlenther Onkol. 2012 Feb;188(2):154-9. doi: 10.1007/s00066-011-0026-7. Epub 2012 Jan 11.

PMID:
22231634
19.

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2015 Dec 28;220(Pt A):348-57. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1.

PMID:
26528901
20.

Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.

Wang Y, Chen X, Zhang Z, Li S, Chen B, Wu C, Wang L, Zhang X, Wang J, Chen L, Jiang T.

Neurosurg Rev. 2014 Jan;37(1):73-8. doi: 10.1007/s10143-013-0490-x. Epub 2013 Aug 3.

PMID:
23912878

Supplemental Content

Support Center